MedTrace Logo

Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis

NCT01461616 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2012-12-04

No results posted yet for this study

Summary

The objective is to describe the interaction of equal doses of NPH insulin (Neutral Protamine Hagedorn), insulin Detemir and insulin glargine on IGFBP-1 (Insulin-like Growth Factor Binding Protein-1) production as well as immunoreactive and bioactive IGF-I (Insulin-like Growth Factor-I) after once-daily injection on three separate visits in type 1 diabetic subjects.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

NPH

equal doses of NPH insulin, insulin Detemir and insulin glargine injection

DRUG

Detemir

equal doses of NPH insulin, insulin Detemir and insulin glargine injection

DRUG

Glargine

equal doses of NPH insulin, insulin Detemir and insulin glargine injection

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Jens Sandahl Christiansen, M.D. · Department of Endocrinology and Internal Medicine, Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01461616 on ClinicalTrials.gov